Inpharmus, originally established in 2013 as TRPharm, rebranded in 2025 to enhance its vision of becoming a global player in the healthcare industry. With its headquarters in Turkey and offices in Istanbul and Dubai, the company actively serves nearly 20 countries and maintains a physical presence in 12 of them.
The company operates in the Health Care and Pharmaceutical industries, leveraging over 100 years of combined experience from its team of doctors and pharmacists. It focuses on healthcare innovations that span the entire process from diagnosis to treatment, creating significant value with the help of global partnerships.
Inpharmus is committed to prioritizing people, fostering transparent partnerships, and balancing science, technology, and ethics. Their approach underlines the company's commitment to drive continuous transformation and innovation, ultimately aiming to leave a lasting impact on the healthcare sector.
It is noteworthy that as of the present, no data on the company's recent investment activities or investors has been disclosed.